Private Trust Co. NA Reduces Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Private Trust Co. NA lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 191 shares of the company’s stock after selling 49 shares during the period. Private Trust Co. NA’s holdings in IDEXX Laboratories were worth $102,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Nordea Investment Management AB raised its stake in shares of IDEXX Laboratories by 4.7% in the second quarter. Nordea Investment Management AB now owns 8,057 shares of the company’s stock valued at $4,298,000 after acquiring an additional 361 shares during the period. Aware Super Pty Ltd as trustee of Aware Super lifted its stake in IDEXX Laboratories by 41.8% in the second quarter. Aware Super Pty Ltd as trustee of Aware Super now owns 62,291 shares of the company’s stock worth $33,409,000 after purchasing an additional 18,375 shares during the last quarter. Alta Capital Management LLC boosted its position in shares of IDEXX Laboratories by 6.0% during the second quarter. Alta Capital Management LLC now owns 22,143 shares of the company’s stock valued at $11,876,000 after buying an additional 1,253 shares during the period. Mutual Advisors LLC bought a new position in shares of IDEXX Laboratories during the second quarter valued at approximately $244,000. Finally, Harbour Investments Inc. raised its holdings in shares of IDEXX Laboratories by 27.3% in the second quarter. Harbour Investments Inc. now owns 98 shares of the company’s stock worth $53,000 after buying an additional 21 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Down 0.5%

NASDAQ:IDXX opened at $633.78 on Thursday. The firm has a 50-day simple moving average of $638.91 and a 200-day simple moving average of $554.07. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $688.12. The firm has a market cap of $50.70 billion, a P/E ratio of 52.77, a P/E/G ratio of 4.12 and a beta of 1.58. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.35. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. IDEXX Laboratories’s revenue was up 10.6% compared to the same quarter last year. During the same period last year, the company posted $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on IDXX shares. JPMorgan Chase & Co. upped their price objective on IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research report on Monday, August 4th. BTIG Research upped their price target on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the stock a “buy” rating in a report on Tuesday, August 5th. Leerink Partners lifted their price objective on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Morgan Stanley upped their target price on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the stock an “overweight” rating in a research note on Friday, August 15th. Finally, Stifel Nicolaus set a $640.00 target price on shares of IDEXX Laboratories in a research report on Monday, August 4th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $656.50.

Insider Activity

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 406 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total value of $263,883.76. Following the completion of the sale, the executive vice president directly owned 11,287 shares in the company, valued at $7,336,098.52. This trade represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sharon E. Underberg sold 5,450 shares of IDEXX Laboratories stock in a transaction on Friday, August 8th. The stock was sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the completion of the transaction, the executive vice president directly owned 6,156 shares in the company, valued at $4,011,249.60. This represents a 46.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 54,057 shares of company stock worth $34,293,468 over the last ninety days. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.